Revance Therapeutics, Inc. provided revenue guidance for the year 2024. The company expects 2024 total product revenue, which includes sales of DAXXIFY and the RHA Collection, to be at least $280 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.16 USD | +4.64% | -4.82% | -64.05% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-64.05% | 330M | |
-3.15% | 89.69B | |
+3.95% | 41.34B | |
-10.51% | 33.72B | |
+58.94% | 26.11B | |
-20.09% | 14.63B | |
-8.92% | 12.84B | |
-11.46% | 11.66B | |
-43.05% | 11.52B | |
+5.39% | 8.92B |
- Stock Market
- Equities
- RVNC Stock
- News Revance Therapeutics, Inc.
- Revance Therapeutics, Inc. Provides Revenue Guidance for the Year 2024